Vobarilizumab
Vobarilizumab (pronunciation: vo-bar-il-iz-u-mab) is a biopharmaceutical drug that is currently under development for the treatment of autoimmune diseases. It is a monoclonal antibody that targets the interleukin-6 receptor (IL-6R), a protein that plays a key role in the inflammatory response of the immune system.
Etymology
The name "Vobarilizumab" follows the INN naming convention for monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the "-lizu-" stem suggests that it targets the immune system.
Mechanism of Action
Vobarilizumab works by binding to the IL-6R and blocking its interaction with interleukin-6 (IL-6), a cytokine that is involved in the inflammatory response. By inhibiting this interaction, Vobarilizumab can reduce inflammation and potentially alleviate the symptoms of autoimmune diseases.
Clinical Trials
Vobarilizumab has been tested in several clinical trials for various autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. The results of these trials have shown promise, but further research is needed to fully understand the drug's efficacy and safety profile.
Related Terms
- Monoclonal antibody
- Interleukin-6 receptor
- Autoimmune disease
- Clinical trial
- Rheumatoid arthritis
- Systemic lupus erythematosus
External links
- Medical encyclopedia article on Vobarilizumab
- Wikipedia's article - Vobarilizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski